

July 18, 2026

BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001, India.

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051, India.

Dear Sir/vMadam,

Subject: Open offer for acquisition of up to 2,77,26,848 (Two Crore Seventy-Seven Lakh Twenty-Six Thousand Eight Hundred Forty-Eight) fully paid-up equity shares of face value of ₹ 1 (Indian Rupee One) each (the “Equity Shares”), of Bliss GVS Pharma Limited (“Target Company”), representing 26.00% (Twenty-Six per cent) of the Expanded Voting Share Capital from the eligible public shareholders of the Target Company by Anupam Rasayan India Limited (“Acquirer”) along with Mates Visa Consultancy Private Limited (“PAC”) in its capacity as person acting in concert with the Acquirer pursuant to and in compliance with the requirements of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 as amended (the “SEBI (SAST) Regulations”) (the “Open Offer”/“Offer”).

With respect to the captioned Offer, we had submitted public announcement dated May 23, 2026; detailed public statement dated June 1, 2026; and Draft Letter of Offer dated June 8, 2026. Further, please refer enclosed a copy of the Addendum to the Public Announcement, Detailed Public Statement and Draft Letter of offer dated July 17, 2026 (“**Addendum**”) for addition of Mates Visa Consultancy Private Limited in its capacity as person acting in concert with the Acquirer.

Kindly take the enclosed Addendum on record.

Capitalized terms used in this letter unless defined herein shall have the same meanings as ascribed to them in the attached LOF.

Thanking You,
Yours truly

SBI Capital Markets Limited



Authorised Signatory

Name: Sylvia Mendonca

Designation: Vice President

Enclosed as stated above